Viking Therapeutics Gains Ground with Promising Oral Weight Loss Treatment

Shares of Viking Therapeutics experienced substantial gains following the release of impressive Phase 2 trial results for its oral formulation of VK2735. The study demonstrated an average weight reduction of up to 12.2 percent after 13 weeks, providing compelling evidence for the drug candidate’s efficacy.

Compelling Trial Results Drive Optimism

The VENTURE-Oral study, which enrolled 280 participants, delivered consistently positive outcomes without showing a plateau effect. Up to 97 percent of treated individuals achieved at least a 5 percent reduction in body weight, while 80 percent of participants lost 10 percent or more.

Safety data remained encouraging, with 98 percent of reported adverse events classified as mild to moderate. These were primarily gastrointestinal issues, which typically emerged at the beginning of treatment and diminished as dosing continued.

Dual-Formulation Strategy Creates Market Potential

Viking is pursuing a distinctive dual-track development approach with both subcutaneous and oral formulations advancing simultaneously. The subcutaneous version is already progressing into Phase 3 trials involving 4,500 participants, while the oral alternative opens new possibilities for maintenance therapy.

Chief Executive Officer Brian Lian highlighted the potential for transitioning patients from higher to lower maintenance doses—a significant advantage over existing treatments where long-term weight management often presents challenges.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Competitive Positioning in Obesity Market

As a dual GLP-1/GIP agonist, VK2735 enters the competitive obesity treatment market against established products such as Wegovy and Zepbound. The oral formulation specifically addresses patient preference for non-injectable therapeutic options.

The company’s manufacturing partnership with CordenPharma ensures production capacity for multi-ton API quantities and over one billion tablets annually. With $808 million in liquid assets, Viking maintains sufficient capital to fund ongoing development efforts.

Upcoming Catalysts and Market Outlook

Future milestones include an additional maintenance dose study and participation in major healthcare conferences scheduled for September. Market analysts identify substantial upside potential with price targets around $90—nearly four times the current trading level.

Whether Viking’s dual-strategy approach can ultimately outperform competitors remains to be seen, but recent clinical data suggests the biotechnology company is positioning itself effectively within the multi-billion dollar obesity therapeutics market.